The global biopharmaceutical market size was estimated at USD 452.21 billion in 2024 and is projected to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030. Market growth is fueled by increasing demand for targeted therapies, rapid biotechnology advancements, the rising burden of chronic diseases, and an expanding elderly population.
Innovation in biologics, personalized medicine, and supportive regulatory pathways for drug approvals also contribute significantly to market expansion. The biopharmaceutical sector is advancing at an accelerated pace due to major breakthroughs in vaccine technology, monoclonal antibodies, gene therapies, and next-generation biologics. These innovations are reshaping treatment standards across a wide range of therapeutic areas by improving efficacy, enhancing patient outcomes, and addressing unmet clinical needs. Recent progress in these technologies underscores the growing influence of biopharmaceuticals in global healthcare and their essential role in disease management.
Growing adoption of biologics and modern therapies further accelerates market growth. As patients and healthcare professionals recognize the superior effectiveness and evolving affordability of advanced treatments, demand rises for innovative therapies that offer improved outcomes with fewer adverse effects. Uptake has been especially strong in oncology, autoimmune disorders, and other high-burden conditions. The rapid use of monoclonal antibodies—particularly in immuno-oncology—continues to transform the therapeutic landscape, with leading products such as Keytruda and Opdivo achieving strong annual sales growth. In July 2024, Amneal Pharmaceuticals, Inc. expanded its biosimilar portfolio with the addition of omalizumab, a monoclonal antibody referencing XOLAIR, used for severe allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria.
Key Market Trends & Insights
- North America biopharmaceutical market remains the largest industry in 2024.
- The U.S. biopharmaceutical industry leads the North America market.
- Based on molecule, the monoclonal antibody (mAb) segment dominated the market, accounting for 61.05% in 2024.
- Based on disease, oncology remained the largest segment, comprising 31.00% of the market in 2024.
- Based on drug type, proprietary (branded) biopharmaceuticals led the market, accounting for 77.86% in 2024.
Download a free sample PDF of the Biopharmaceutical Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 452.21 Billion
- 2030 Projected Market Size: USD 740.84 Billion
- CAGR (2025–2030): 8.87%
- North America: Largest market in 2024
Competitive Landscape
Key players in the global market include AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Inc., Roche Holding, and Sanofi. Market leaders continue to invest in developing and enhancing technologies to improve patient outcomes and strengthen healthcare efficiency.
Prominent Companies
- F. Hoffmann-La Roche Ltd
- Novartis AG
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Sanofi
- GSK plc.
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The biopharmaceutical market is poised for strong and sustained expansion as technological innovation, rising therapeutic demand, and supportive regulatory frameworks converge to reshape modern healthcare. With continued breakthroughs in biologics, gene therapies, and targeted treatments, industry leaders are well-positioned to deliver transformative solutions that improve patient outcomes and address global health challenges. If you'd like, I can create a shorter, more executive-ready, or more technical conclusion.
No comments:
Post a Comment